Edwards Lifesciences(NYSE) EW

Edwards Lifesciences Corporation makes medical devices for heart conditions.

Its products help doctors replace or repair damaged heart valves.

These tools allow for treatments without using open-heart surgery.

What Does Edwards Make?

• Transcatheter Aortic Valve Replacement: Heart valves used for minimally invasive procedures; generated $2.5 billion in net sales during the first half of 2026.
• Transcatheter Mitral and Tricuspid Therapies: Systems designed to repair or replace valves for patients with mitral and tricuspid diseases; generated $373.7 million in net sales during the first half of 2026.
• Surgical Structural Heart: Advanced surgical valves and conduits used in traditional heart surgeries; generated $560.3 million in net sales during the first half of 2026.

New Valves and New Ventures

• Acquired Autus Valve Technologies in February 2026 for $128.9 million to expand its valve technology portfolio.
• Sold the Critical Care product group to Becton, Dickinson and Company in September 2024 to focus on structural heart disease.
• Received United States Food and Drug Administration approval for the SAPIEN 3 transcatheter pulmonic valve in January 2026.
• Gained CE Mark approval for the SAPIEN M3 RESILIA valve in June 2026 to increase access for European patients.
• Received FDA approval for TRIFORMIS RESILIA, a surgical tricuspid valve replacement, in May 2026.

A Focus on Heart Innovation

The company manages global operations across the United States, Europe, Japan, and other international regions. It maintains a patient-focused culture that prioritizes clinical evidence and intellectual property for its structural heart technologies.

The Latest Numbers

• Total net sales were $3.4 billion in the first six months of 2026, up 15.1% year over year.
• Sales for the Transcatheter Mitral and Tricuspid Therapies group rose 49.6% year over year during the first half of 2026.
• Net cash provided by operating activities was $695.7 million for the six-month period ended June 30, 2026.
• The company repurchased 6.9 million shares of its common stock for $558.7 million during the first half of 2026.
• Research and development expenses increased in the first half of 2026 due to investments in heart failure management.

A Targeted Heart Strategy

Edwards has transitioned into a specialized firm focused on implantable heart innovations by divesting its monitoring and non-core businesses. The company uses clinical data and new product launches to maintain its position in the structural heart market.